The UK and US have concluded a important commercial pact that will preserve no import taxes on UK pharmaceutical exports being sold in the US market.
Key Provisions of the Pact
As part of the deal, the UK has agreed to raise funding on pharmaceuticals through the National Health Service (NHS). This move secures that duties on these crucial exports will stay at zero for a period of the next three years.
This development follows previous statements to hike duties on patented drug imports, with potential rates mentioned as high as double the cost.
"This agreement with the UK bolsters the global environment for cutting-edge drugs and establishes much-needed fairness to American-British medicine commerce," a release said.
Trade Significance
Drugs constitute one of the UK's biggest exports to the United States, which is by far the biggest buyer for leading companies like GSK and AstraZeneca.
Statistics reveal that in the 12 months prior to the third quarter, the UK shipped medicines valued at billions to the US. This figure made up 17.4% of British export trade in that period.
"This guarantee secures jobs, boosts investment and sets the stage for the UK to establish itself as a international leader for life sciences," the Business and Trade Secretary stated.
Key British Pledges
The deal entails several notable pledges from the United Kingdom:
- Price Threshold Increase: The UK will lift the affordability limit at which it judges new therapies to be prohibitively costly by twenty-five percent.
- Higher Drug Budget: There is a target to raise overall NHS spending on drugs from 0.3% of Gross Domestic Product to 0.6% over the next decade.
- Rebate Cap: The amount pharmaceutical firms must return to the NHS to control costs will be restricted at 15%. Previously, repayments topped twenty percent.
Recent Tensions
This agreement follows a long-running tension between the drug companies and the UK government over drug pricing and regulatory access.
The disagreement were exacerbated by arguments that US consumers were paying significantly more for the same drugs than people in the Britain and the EU.
Recently, several significant pharmaceutical investments in the UK have been delayed or abandoned, while multi-billion-dollar expansions have been announced toward US facilities.
A senior figure stated that the NHS must increase expenditure on treatments, noting that its spending on drugs had declined as a proportion of its total funding over the past decade.
